leflunomide / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 88 Diseases   68 Trials   68 Trials   2888 News 


«12...2324252627282930313233...3536»
  • ||||||||||  leflunomide / Generic mfg.
    Enrollment open:  Leflunomide in Mild COVID-19 Patients (clinicaltrials.gov) -  May 10, 2020   
    P1,  N=20, Recruiting, 
    Not yet recruiting --> Recruiting
  • ||||||||||  Review, Journal:  Strategies toward rheumatoid arthritis therapy; the old and the new. (Pubmed Central) -  May 7, 2020   
    The biological therapies, on the contrary, are chimeric anti-CD20 monoclonal antibody, rituximab, inhibitors of tumor necrosis factor-α (TNF-α) like etanercept, infliximab, and adalimumab, a recombinant inhibitor of interleukin-1 (IL-1), anakinra, and costimulation blocker, abatacept...The probability of remission increase if the diagnosis happens rapidly and treat-to-target approach are implemented. In this review article, we have attempted to go through the treatment strategies for RA therapy both the routine ones and those which have been developed over the past few years and currently under investigation.
  • ||||||||||  Actemra IV (tocilizumab) / Roche, JW Pharma, Rituxan (rituximab) / Roche, Biogen, Zenyaku Kogyo
    Review, Journal:  Refractory Sarcoidosis: A Review. (Pubmed Central) -  May 6, 2020   
    That is when second-line treatments, immunosuppressants (methotrexate, leflunomide, azathioprine, mycophenolate mofetil, hydroxychloroquine), should be considered...Among them, anti-CD20 antibodies (rituximab), repository corticotrophin injection, and anti-JAK therapy anti-interleukin-6 receptor monoclonal antibody (tocilizumab) were the main reported...Currently, other immunosuppressants such as JAK inhibitors are on trial to assess their efficacy in sarcoidosis. In this review, we propose to summarize the state of the art regarding the use of immunosuppressants and their management in the case of refractory or multidrug-resistant sarcoidosis.
  • ||||||||||  Clinical, Retrospective data, Journal:  Favorable retention rates and safety of conventional anti-rheumatic drugs in older patients with rheumatoid arthritis. (Pubmed Central) -  Apr 30, 2020   
    In the analysis of drug retention rates, there was no significant difference between the ERA and YRA groups for each conventional DMARD (methotrexate 71.2% in ERA, 62.7% in YRA, P = .817; hydroxychloroquine 82.9% in ERA, 78.8% in YRA, P = .899; leflunomide 81.4% in ERA, 84.4% in YRA, P = .205; sulfasalazine 37.5% in ERA, 40.9% in YRA, P = .380). The adverse event data were also similar in both groups.The drug retention and adverse effect rates in older patients with RA using conventional DMARDS are similar to the rates in young patients with RA.
  • ||||||||||  leflunomide / Generic mfg.
    New P1 trial:  Leflunomide in Mild COVID-19 Patients (clinicaltrials.gov) -  Apr 23, 2020   
    P1,  N=20, Not yet recruiting, 
  • ||||||||||  Orencia (abatacept) / BMS, Rituxan (rituximab) / Roche, Biogen, Zenyaku Kogyo
    Journal:  EULAR recommendations for the management of Sjögren's syndrome with topical and systemic therapies. (Pubmed Central) -  Apr 22, 2020   
    The recommendations synthesise current thinking on SjS treatment in a set of overarching principles and recommendations. We hope that the current recommendations will be broadly applied in clinical practice and/or serve as a template for national societies to develop local recommendations.
  • ||||||||||  Vistide (cidofovir) / Gilead, carbamazepine / Generic mfg.
    [VIRTUAL] Severe human herpesvirus 7 (HHV-7) encephalitis in a patient with rheumatoid arthritis (Room: Screen B6) -  Apr 9, 2020 - Abstract #EAN2020EAN_1465;    
    The pathogenic role of HHV-7 in encephalitis is controversial but it should be considered and aggressively treated in immunosuppressed patients. The current case reports the evolution of HHV-7 encephalitis which can contribute to the current knowledge of this serious disease.
  • ||||||||||  TriptoSar (triptolide) / Pierre Fabre
    Preclinical, Journal:  Effect of Triptolide on Cardiac Function in Arthritic Rats and Its Mechanism (Pubmed Central) -  Apr 3, 2020   
    The expressions of Keap1, maf and Nrf2 mRNAs and proteins in the heart tissues of the triptolide group were decreased ( P<0.01). Triptolide could improve cardiac function in arthritic rats, and the mechanism may related to its ability of improving the anti-oxidationin cardiomyocytes, reducing oxidative stress damage, and inhibiting abnormal immune inflammatory response.
  • ||||||||||  methotrexate / Generic mfg., leflunomide / Generic mfg.
    Clinical, Journal:  Effect of Moxibustion on HIF-1α and VEGF Levels in Patients with Rheumatoid Arthritis. (Pubmed Central) -  Apr 2, 2020   
    The reductions of HIF-1α and VEGF in the treatment group were superior to the control group (P < 0.05). Moxibustion enhanced the anti-inflammatory and analgesic effects of conventional medicine and can enhance the effect of conventional medicine, downregulating HIF-1α/VEGF contents to inhibit angiogenesis.
  • ||||||||||  leflunomide / Generic mfg.
    Journal:  Leflunomide treatment in juvenile idiopathic arthritis. (Pubmed Central) -  Apr 1, 2020   
    Only two adverse events resolving within 2 weeks were noted (Lymphopenia = 1, elevated liver enzymes = 1). LFN may be an alternative therapy in case of MTX intolerance or toxicity.
  • ||||||||||  Enrollment open:  POISE: Psoriatic Oligoarthritis Intervention With Symptomatic thErapy (clinicaltrials.gov) -  Mar 27, 2020   
    P4,  N=60, Recruiting, 
    The associated predictors were rheumatoid arthritis, small and medium joints, lower pain/swelling visual analog scale scores, and use of leflunomide. Not yet recruiting --> Recruiting
  • ||||||||||  teriflunomide / Generic mfg., leflunomide / Generic mfg.
    Review, Journal:  Revisiting the role of dihydroorotate dehydrogenase as a therapeutic target for cancer. (Pubmed Central) -  Mar 26, 2020   
    We then explore the preclinical and clinical results of pharmacological strategies to target the de novo pyrimidine biosynthesis pathway, with a highlight on DHODH. Finally, we discuss potential strategies to harness DHODH as a target for the treatment of cancer.
  • ||||||||||  Leustatin (cladribine) / J&J, Tecfidera (dimethyl fumarate) / Biogen, Mavenclad (cladribine) / EMD Serono
    Journal:  Oral Therapies for Multiple Sclerosis. (Pubmed Central) -  Mar 24, 2020   
    Until now, the four orally available medications, fingolimod, dimethylfumarate (BG-12), teriflunomide, and cladribine have received market authorization, whereas laquinimod is still under development...In addition, there are three more specific S1P agonists in late stages of development: siponimod, ponesimod, and ozanimod...Teriflunomide, the active metabolite of the rheumatoid arthritis medication leflunomide, targets the dihydroorotate dehydrogenase, thus inhibiting the proliferation of lymphocytes by depletion of pyrimidines. Here we will review the mechanisms of action, clinical trial data, as well as data about safety and tolerability of the compounds.
  • ||||||||||  Humira (adalimumab) / Eisai, AbbVie, Rituxan (rituximab) / Roche, Biogen, Zenyaku Kogyo
    The Knowledge and Practices of Rheumatologists and Pulmonologists in Rheumatoid Arthritis-Associated Interstitial Lung Disease (PENNSYLVANIA CONVENTION CENTER, Hall D-E (200 Level), Area D) -  Mar 15, 2020 - Abstract #ATS2020ATS_9415;    
    In spite of only 24% of respondents believing that methotrexate is a risk factor for RA-ILD, 60% avoid it in patients with RA-ILD...In addition, the attitudes and practices of providers diagnosing and managing RA-ILD are significantly influenced by years of experience and practice setting. Given the potential emergence of newer therapies for RA-ILD, these data highlight the need for clinical guidelines in the diagnosis and management of RA-ILD.
  • ||||||||||  Refractory Sarcoidosis and Use of Repository Corticotropin Injection (RCI): A Case Series (PENNSYLVANIA CONVENTION CENTER, Hall D-E (200 Level), Area H) -  Mar 15, 2020 - Abstract #ATS2020ATS_7956;    
    She had persistent shortness of breath, cough and chest pain despite the use of prednisone 15mg/day, leflunomide, and azathioprine...Initial regimen included methylprednisolone 32mg/day and leflunomide...Apart from corticosteroids, other therapies for sarcoidosis include azathioprine, mycophenolate mofetil, leflunomide, cyclophosphamide, infliximab, and rituximab...Current prospective studies show significant reductions in exogenous steroid dosage and improvement in pulmonary function with RCI use. However, further randomized studies are necessary to establish its efficacy over corticosteroids.
  • ||||||||||  leflunomide / Generic mfg.
    Leflunomide-Induced Interstitial Pneumonitis: A Rare Occurrence in a Case Without Underlying Lung Disease (PENNSYLVANIA CONVENTION CENTER, Hall D-E (200 Level), Area G) -  Mar 15, 2020 - Abstract #ATS2020ATS_7853;    
    Leflunomide should be used with caution in RA patients with risk factors, and loading doses should be avoided. LEIP should be in the differential for acute respiratory symptoms in this patient population to prevent delay in treatment with steroids and specifically cholestyramine washout therapy.
  • ||||||||||  leflunomide / Generic mfg.
    Leflunomide Induced Eosinophilic Bronchitis (PENNSYLVANIA CONVENTION CENTER, Hall D-E (200 Level), Area G) -  Mar 15, 2020 - Abstract #ATS2020ATS_7852;    
    After discontinuing the leflunomide, first line treatment is corticosteroids. Eosinophilic bronchitis should be considered in the differential diagnosis of cough for all patients to whom leflunomide is prescribed.
  • ||||||||||  Remicade (infliximab) / Mitsubishi Tanabe, J&J, Humira (adalimumab) / Eisai, AbbVie
    Optic Neuritis in Sarcoidosis: Clinical Features and Response to Therapy (PENNSYLVANIA CONVENTION CENTER, Hall D-E (200 Level), Area A) -  Mar 15, 2020 - Abstract #ATS2020ATS_5226;    
    It is associated with other ocular and neurologic manifestations of sarcoidosis. It usually requires second and third line therapy.
  • ||||||||||  [VIRTUAL] SWITCH TO BIOSIMILAR ADALIMUMAB - IS IT COST EFFECTIVE? (Poster Tour) -  Mar 4, 2020 - Abstract #EULAR2020EULAR_879;    
    All were happy to switch after receiving a letter and having the opportunity to contact if necessary. Substantial annual cost savings of over £300,000 have been projected for this financial year.
  • ||||||||||  hydroxychloroquine / Generic mfg., methotrexate / Generic mfg., leflunomide / Generic mfg.
    [VIRTUAL] DRUG-RELATED PANCYTOPENIA AND LEUKOPENIA IN RHEUMATOID ARTHRITIS: ARE ALL CSDMARDS EQUAL? (Poster Tour) -  Mar 4, 2020 - Abstract #EULAR2020EULAR_801;    
    Cytopaenia is rare, and apparently more frequent with MTX and less with LEF. Since prior full blood counts were inconsistently obtained in fewer than 50% of csDMARD new users (e.g. more frequent in MTX [42%] than HCQ [32%] in CCAE and Optum; roughly equal in MDCR), these results should inform future monitoring recommendations.
  • ||||||||||  Tai'ai (telitacicept) / Rongchang Pharma
    Trial completion, Trial completion date, Trial primary completion date:  Study of RC18 Administered Subcutaneously to Subjects With Systemic Lupus Erythematosus(SLE) (clinicaltrials.gov) -  Mar 4, 2020   
    P2b,  N=249, Completed, 
    No unexpected safety signals were found for either agent. Active, not recruiting --> Completed | Trial completion date: Dec 2019 --> Jul 2019 | Trial primary completion date: Dec 2019 --> Jun 2019
  • ||||||||||  valsartan / Generic mfg., cyclophosphamide intravenous / Generic mfg., leflunomide / Generic mfg.
    Retrospective data, Review, Journal:  Efficacy and safety of leflunomide in IgA nephropathy: a systematic review and meta-analysis. (Pubmed Central) -  Mar 2, 2020   
    LEF appears to improve renal function while decreasing loss of urine protein. Combination regimens including LEF were better and safer compared with CS or ACEI alone or combinations including CTX.